ERCC1 and cervical adenocarcinoma: There was an association between ERCC1 expression and sensitivity to cisplatin in cervical adenocarcinoma cells. A cisplatin-resistant cell line HCA-1R showed a dramatically higher level of ERCC1 mRNA expression than the native cells. Co-administration of cisplatin and 5-FU showed the synergistic or additive effects via inhibiting of ERCC1 expression.